Opthea To Present at the Ophthalmology Innovation Summit in San Francisco
4 October 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at the Ophthalmology Innovation…
Cartherics Pty Ltd to Present at 2019 Cell & Gene Meeting on the Mesa
1 October 2019 Melbourne, Australia, – Cartherics Pty Ltd announced today that Professor Richard Boyd, Chief Scientific Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.…
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
26 September 2019 • Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 • Recruitment of cohort 2 of Part A…
Opthea Receives A$14.6m R&D Tax Incentive
1 October, 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today it received a A$14.6 million research and development (R&D) tax credit from the Australian Taxation…
Medical Device Partnering Program (MDPP Victoria) drop-in sessions
11 September 2019 Calling all Victorian-based stakeholders! Keep an eye out as the Medical Device Partnering Program (MDPP) will be in your neighbourhood! Drop-In sessions will run for the next few weeks as part of our ongoing strategy to…
Collaboration Agreement signed between GTG and The Translational Genomics Research Institute (TGen) of Phoenix, Arizona USA
24 September 2019 Genetic Technologies Limited (“Company”), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen. TGen, an affiliate of City of Hope in Duarte, California,…
Immutep to receive £4M milestone payment from GSK
23 September 2019 Sydney, Australia – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it will receive a milestone payment from GSK…
Victorian Government News
18 September 2019 The Hon Martin Pakula, Minister for Jobs, Innovation and Trade, recently attended the kick-off of the Medtech Actuator’s first national sprint meeting and engaged with the MedTech Actuator Accelerator Program’s fourth cohort. Following the Minister’s…
Delivering Value To Our Members – ARMI
17 September 2019 When the Australian Regenerative Medicine Institute at Monash University needed help to boost industry awareness of its work and interact with the growing regenerative medicine sector, the BioMelbourne Network helped with contacts and hosted a…
Monash University students helping to reduce the spread of mosquito-borne disease
17 September 2019 A Monash University student has spent five weeks conducting immersive research at the World Mosquito Program’s (WMP) Fiji site. Fiji experiences regular bouts of vector-borne disease and the program has operated there since 2018. Tanaya…
AdAlta secures licensing deal for the i-body platform with global medical technology and diagnostics firm, GE Healthcare
16 September 2019 Melbourne Australia: AdAlta Limited (ASX:1AD), today announced it has signed a commercial agreement for its i-body platform with global medical technology firm, GE Healthcare. Financial terms were not disclosed. The licensing deal will see the…
European Union Regulatory Certification and MRSA Study Results: APAS® Independence available for sale in European Union
16 September 2019 Adelaide, Australia: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce that the Conformité Européene or CE Mark…
